These data support the hypothesis that a Kallmann syndrome-associated mutation causes hyperactivity of the negative FGF-regulator Spry4 and demonstrate that this version is additionally able to interfere with RTK-mediated processes in malignant cells. This evidence concerns the gene SPRY4 and Kallmann syndrome.